Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Dovetail Genomics Adds PacBio SMRT Sequencing and Assembly to Its Services Menu

Dovetail Genomics
Posted on: 23 Sep 16

MENLO PARK, Calif. and SANTA CRUZ, Calif., Sept. 22, 2016 /PRNewswire/ -- Pacific Biosciences of California, Inc., (Nasdaq: PACB), and Dovetail Genomics™ LLC today announced that Dovetail has added PacBio® SMRT® sequencing and de novo assembly options to its menu of genome assembly services. The companies also announced their signing of a co-marketing agreement under which the new service offerings will be jointly promoted.

"We are impressed by Dovetail's continued commitment to deliver the most comprehensive view of genomes," said Kevin Corcoran, Senior Vice President of Market Development at Pacific Biosciences. "Until now, Dovetail has focused exclusively on short-read NGS data, so we are pleased to see the addition of our long-read SMRT Sequencing technology to their service offering, and to partner with Dovetail to provide the best possible genome assemblies to the scientific community."

"The addition of these services is in direct response to our customers' needs," said Brandon Rice, Dovetail Genomics' Chief Operations Officer, "so we are excited to provide this option for our customers who need, or simply prefer, a long-read sequencing approach for their genome assembly projects."

PacBio SMRT Sequencing delivers long read lengths with high consensus accuracy and uniform coverage, allowing scientists to go beyond fragmented draft genomes and generate the most comprehensive de novo assemblies. Dovetail found through its services that its approach to scaffolding with Chicago™ libraries and its HiRise™ scaffolding pipeline are highly complementary to PacBio-based assemblies. This new offering is especially valuable to scientists working on highly repetitive, polyploid genomes that are challenging to resolve with short-read sequencing alone.

The two companies will begin co-marketing the Dovetail service offering immediately. Interested parties can learn more here.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at

About Dovetail Genomics

Dovetail Genomics LLC is transforming genomics by making long-range information readily accessible to all. The company enables researchers and clinicians to solve complex problems involving de novo assembly, structural variation, microbiome analysis, cancer research, phasing analysis and more by providing them a more comprehensive view of the genome. Its proprietary in vitro proximity ligation approach simplifies genomic discovery by integrating the highest quality long-range genomic information with next-gen sequencing output. Dovetail is based in Santa Cruz, California. For more information on Dovetail, its technology and service offerings, visit Follow Dovetail on Twitter @DTGenomics.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future availability, uses, quality or performance of, or benefits of using, products or technologies, expected benefits of the agreement between Pacific Biosciences and Dovetail Genomics and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences' control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences' most recent filings with the Securities and Exchange Commission, including Pacific Biosciences' most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors."

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

For more information:

Editor's Details

Mike Wood

Last updated on: 23/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.